MY194920A - Polysaccharide ? protein conjugates with enhanced immunogenicity and rapid high yielding process thereof - Google Patents
Polysaccharide ? protein conjugates with enhanced immunogenicity and rapid high yielding process thereofInfo
- Publication number
- MY194920A MY194920A MYPI2016701265A MYPI2016701265A MY194920A MY 194920 A MY194920 A MY 194920A MY PI2016701265 A MYPI2016701265 A MY PI2016701265A MY PI2016701265 A MYPI2016701265 A MY PI2016701265A MY 194920 A MY194920 A MY 194920A
- Authority
- MY
- Malaysia
- Prior art keywords
- polysaccharide
- protein
- protein conjugates
- present
- enhanced immunogenicity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Materials Engineering (AREA)
- Pulmonology (AREA)
- Sustainable Development (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2363DE2014 | 2014-08-20 | ||
PCT/IB2014/065201 WO2015052684A2 (en) | 2013-10-11 | 2014-10-10 | Polysaccharide-protein conjugates with enhanced immunogenicity and rapid high yielding process thereof |
IN3047DE2013 IN2013DE03047A (zh) | 2013-10-11 | 2014-10-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
MY194920A true MY194920A (en) | 2022-12-23 |
Family
ID=52144766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI2016701265A MY194920A (en) | 2013-10-11 | 2014-10-10 | Polysaccharide ? protein conjugates with enhanced immunogenicity and rapid high yielding process thereof |
Country Status (4)
Country | Link |
---|---|
CN (1) | CN105636608A (zh) |
MY (1) | MY194920A (zh) |
WO (1) | WO2015052684A2 (zh) |
ZA (1) | ZA201602375B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105770890A (zh) * | 2016-03-08 | 2016-07-20 | 苏文全 | 一种特异性蛋白质组合物及其使用方法 |
CN106084037B (zh) * | 2016-06-08 | 2020-01-07 | 中国人民解放军第二军医大学 | 一种炭疽杆菌荚膜表面三糖缀合物及其制备方法和应用 |
MX2019002489A (es) | 2016-09-02 | 2019-10-21 | Sanofi Pasteur Inc | Vacuna contra neisseria meningitidis. |
KR102388325B1 (ko) | 2016-10-20 | 2022-04-18 | 케이엠 바이올로직스 가부시키가이샤 | 저분자화 PRP를 사용한 Hib 컨쥬게이트 백신의 제조방법 |
CN114965784B (zh) * | 2022-06-01 | 2023-10-27 | 艾美探索者生命科学研发有限公司 | 多糖活化度的测定方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3828145B2 (ja) * | 1993-09-22 | 2006-10-04 | ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン | 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法 |
US8048432B2 (en) * | 2003-08-06 | 2011-11-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Polysaccharide-protein conjugate vaccines |
GB201103836D0 (en) * | 2011-03-07 | 2011-04-20 | Glaxosmithkline Biolog Sa | Conjugation process |
-
2014
- 2014-10-10 MY MYPI2016701265A patent/MY194920A/en unknown
- 2014-10-10 CN CN201480056001.6A patent/CN105636608A/zh active Pending
- 2014-10-10 WO PCT/IB2014/065201 patent/WO2015052684A2/en active Application Filing
-
2016
- 2016-04-08 ZA ZA2016/02375A patent/ZA201602375B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN105636608A (zh) | 2016-06-01 |
WO2015052684A3 (en) | 2015-07-23 |
WO2015052684A2 (en) | 2015-04-16 |
ZA201602375B (en) | 2017-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY194920A (en) | Polysaccharide ? protein conjugates with enhanced immunogenicity and rapid high yielding process thereof | |
MX2020002558A (es) | Procesos para la formulacion de polisacaridos neumococicos para la conjugacion a una proteina transportadora. | |
EA201391788A1 (ru) | Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae | |
MX2021014710A (es) | Un conjugado inmunogenico de polisacarido de neumococo del serotipo 35b- proteina y proceso de conjugacion para preparar el mismo. | |
CY1112677T1 (el) | Εμβολιο συζευγμενου πνευμονοκοκκικου πολυσακχαριδιου | |
MX354103B (es) | Composicion inmunogenica. | |
WO2015012904A3 (en) | Antibody-sn-38 immunoconjugates with a cl2a linker | |
PH12018501517B1 (en) | Neisseria meningitidis compositions and methods thereof | |
PH12015500390B1 (en) | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis | |
EP2601969A3 (en) | Norovirus vaccine formulations | |
BRPI0413323B8 (pt) | método para a preparação de uma vacina meningocócica conjugada ao toxóide tetânico em volumes comerciais | |
MX351345B (es) | Proceso de conjugación de polisacáridos bacterianos con proteínas portadoras. | |
TN2014000148A1 (en) | Antigen binding protein and its use as addressing product for the treatment of cancer | |
CL2011002369A1 (es) | Una composicion inmunogenica que comprende: un sacarido capsular neumococico conjugado, incluyendo sacarido depolimerizado de serotipo 18c; y antigeno de proteina de union a factor h (fhbp) meningococico, pero sin incluir vesiculas de membrana meningococida. y metodo de preparacion de la composicion. | |
AR080122A1 (es) | Composicion de vacuna conjugada de polisacarido-proteina neumococica 15-valente | |
CL2007003781A1 (es) | Metodo para la elaboracion de un conjugado inmunogenico que comprende el polisacarido del serotipo 1 de streptococcus pneumoniae covalentemente unido a una proteina vehiculo; y proceso para preparar una composicion inmunogenica multivalente polisacarido-proteina. | |
JO2840B1 (en) | vaccine | |
WO2011156774A3 (en) | Multivalent glycopeptide constructs and uses thereof | |
WO2009060281A3 (en) | Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties | |
MX2018010920A (es) | Nuevos conjugados de polisacarido-proteina, y procedimiento para obtener los mismos. | |
TN2017000126A1 (en) | An improved process of conjugation and novel synthetic oligosaccharide- protein conjugates obtained thereof | |
MX2020002084A (es) | Conjugados de peptido, proceso de conjugacion y usos de los mismos. | |
IN2013DE03047A (zh) | ||
EA201391202A1 (ru) | Способ получения множественных антигенных гликопептид-углеводных конъюгатов | |
IN2014MU00349A (zh) |